🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Australia / NCT07552922
Recruiting Not applicable

Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Stage 1

NCT07552922 · tracked via the Priya Life Science Australia tracker
Phase
Not applicable
Started
2025-12-01
Last updated
2026-04-27

Condition(s) studied

Prostate Cancer (Adenocarcinoma)

Investigational drug(s) / intervention(s)

Semi-structured Interview

Semi-structured Interview: this t study will use qualitative methods to explore men's views of gynaecomastia from high-risk BCR PCa treatments (Stage 1) to inform attributes and levels for a later DCE to examine patient treatment preferences (Stage 2).

Study summary

This study aims to explore the perceptions of men with prostate cancer (PCa) and high-risk biochemical recurrence (BCR) regarding the risk of breast-related side effects, including gynaecomastia, from treatment.

Eligibility

Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Men with high-risk BCR PCa but no ADT+/-ARPI experience. * Men with ADT+/-ARPI experience who have experienced breast-related side effects from this treatment. Exclusion Criteria: • Men receiving psychiatric care as a consequence of their prostate cancer diagnosis or treatment thereof.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Kinghorn Cancer Centre Sydney New South Wales Recruiting

More St Vincent's Hospital, Sydney trials in Australia

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07552922 on ClinicalTrials.gov ↗ ← All trials in Australia